1. Clinical Trials Targeting Secondary Damage after Traumatic Spinal Cord Injury
- Author
-
Khaing, Zin Z, Chen, Jessica Y, Safarians, Gevick, Ezubeik, Sohib, Pedroncelli, Nicolas, Duquette, Rebecca D, Prasse, Tobias, and Seidlits, Stephanie K
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Medicinal and Biomolecular Chemistry ,Chemical Sciences ,Microbiology ,Traumatic Head and Spine Injury ,Clinical Research ,Neurodegenerative ,Physical Injury - Accidents and Adverse Effects ,Spinal Cord Injury ,Neurosciences ,Regenerative Medicine ,Clinical Trials and Supportive Activities ,Neurological ,Injuries and accidents ,Humans ,Neuroprotective Agents ,Quality of Life ,Spinal Cord ,Spinal Cord Injuries ,Clinical Trials as Topic ,biomaterials ,spinal cord injury repair ,acute and sub-acute strategies ,neuroprotective therapies ,Other Chemical Sciences ,Genetics ,Other Biological Sciences ,Chemical Physics ,Biochemistry and cell biology ,Medicinal and biomolecular chemistry - Abstract
Spinal cord injury (SCI) often causes loss of sensory and motor function resulting in a significant reduction in quality of life for patients. Currently, no therapies are available that can repair spinal cord tissue. After the primary SCI, an acute inflammatory response induces further tissue damage in a process known as secondary injury. Targeting secondary injury to prevent additional tissue damage during the acute and subacute phases of SCI represents a promising strategy to improve patient outcomes. Here, we review clinical trials of neuroprotective therapeutics expected to mitigate secondary injury, focusing primarily on those in the last decade. The strategies discussed are broadly categorized as acute-phase procedural/surgical interventions, systemically delivered pharmacological agents, and cell-based therapies. In addition, we summarize the potential for combinatorial therapies and considerations.
- Published
- 2023